ReviewTherapeutic advances in gastroenterology2018
Inflammatory bowel disease: towards a personalized medicine.
Review in Therapeutic advances in gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Pooled it
- The effectiveness of continuity of care in patients with inflammatory bowel disease: a systematic review.BMC gastroenterology · 2024Pooled it
- Epidemiological, Clinical, Patient-Reported and Economic Burden of Inflammatory Bowel Disease (Ulcerative colitis and Crohn's disease) in Spain: A Systematic Review.Advances in therapy · 2023Pooled it
- A systematic review and functional bioinformatics analysis of genes associated with Crohn's disease identify more than 120 related genes.BMC genomics · 2022Pooled it
- Filgotinib Improved Health-Related Quality of Life and Led to Comprehensive Disease Control in Individuals with Ulcerative Colitis: Data from the SELECTION Trial.Journal of Crohn's & colitis · 2023Trial
- Patient-derived tissue slice cultures from endoscopic biopsies as a translational ex vivo model for inflammatory bowel diseases.Clinical and experimental medicine · 2026Article
- mHealth Use, Preferences, Barriers, and eHealth Literacy Among Patients With Inflammatory Bowel Disease: Survey Study.JMIR human factors · 2025Article
- Leveraging Organ-on-Chip Models to Investigate Host-Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease.Advanced healthcare materials · 2025Review
- Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.Journal of Crohn's & colitis · 2024Observational
- Person-Centered Coordinated Care Experience of People With Long-Term Conditions in the Balearic Islands Measured by the P3CEQ.Health services insights · 2024Article
- Precision medicine in inflammatory bowel disease.Precision clinical medicine · 2023Review
- Current status of novel biologics and small molecule drugs in the individualized treatment of inflammatory bowel disease.World journal of gastroenterology · 2022Review
- Early Diagnosis, Early Stratification, and Early Intervention to Deliver Precision Medicine in IBD.Inflammatory bowel diseases · 2022Review
- Cytokine responses in nonlesional psoriatic skin as clinical predictor to anti-TNF agents.The Journal of allergy and clinical immunology · 2022Article
- Alterations and Potential Applications of Gut Microbiota in Biological Therapy for Inflammatory Bowel Diseases.Frontiers in pharmacology · 2022Review
- Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease.Frontiers in medicine · 2022Review
- Article
- The four epidemiological stages in the global evolution of inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2021Review
- How to Optimize Treatment With Ustekinumab in Inflammatory Bowel Disease: Lessons Learned From Clinical Trials and Real-World Data.Frontiers in medicine · 2021Review
- Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues.Therapeutic advances in gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of inflammatory bowel disease (IBD) has been transformed over the last two decades by the arrival of tumor necrosis factor (TNF) antagonist agents. Recently, alternative drugs have been approved, directed at leukocyte-trafficking molecules (vedolizumab) or other inflammatory cytokines (ustekinumab). New therapeutics are currently being developed in IBD and represent promising targets as they involve other mechanisms of action (JAK molecules, Smad 7 antisense oligonucleotide etc.). Beyond TNF antagonist agents, these alternative drugs are needed for early-stage treatment of patients with aggressive IBD or when the disease is resistant to conventional therapy. Personalized medicine involves the determination of patients with a high risk of progression and complications, and better characterization of patients who may respond preferentially to specific therapies. Indeed, more and more studies aim to identify factors predictive of drug response (corresponding to a specific signaling pathway) that could better manage treatment for patients with IBD. Once treatment has started, disease monitoring is essential and remote patient care could in some circumstances be an attractive option. Telemedicine improves medical adherence and quality of life, and has a positive impact on health outcomes of patients with IBD. This review discusses the current application of personalized medicine to the management of patients with IBD and the advantages and limits of telemedicine in IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.